Background: Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein belonging to the fibrinogen-related protein superfamily, which plays multifaceted roles in innate immunity and normal endothelial function. It has been proposed that MFAP4 promotes the development of asthma in vivo and proasthmatic pathways of bronchial smooth muscle cells in vitro. The aim of this study was to investigate the significance of serum MFAP4 in adolescents and young adolescents with persistent asthma.
Methods: Prospective, observational study including adolescents and young adults (age 11-27 years) previously diagnosed with asthma during childhood 2003 to 2005 (0-15 years) at the four pediatric outpatient clinics in the Region of Southern Denmark (n = 449). Healthy controls were recruited at follow-up (n = 314). Detection of serum MFAP4 was performed by AlphaLISA technique.
Results: Current asthma was associated to a 14% higher mean level of serum MFAP4 compared with controls (expβ 1.14, 95% confidence intervals [CI], 1.05-1.23) and a 6% higher mean level compared with subjects with no current asthma (expβ 1.06, 95% CI, 0.99-1.13). No association was found at follow-up between serum MFAP4 and self-reported atopic symptoms (other than asthma), Asthma Control Test-score, fractional exhaled nitric oxide (FeNO), nor to flow rate at 1 second, forced vital capacity, and forced expiratory flow 25% to 75%, response to short-acting beta 2 agonist or mannitol.
Conclusions: We found a significantly higher mean level of serum MFAP4 in adolescent and young adults with mild to moderate asthma compared with healthy controls but no association to FeNO and lung function nor to the response to short-acting beta 2 agonist or mannitol. The result supports the hypothesis that MFAP4 plays a role in the pathogenesis of asthma although the marker did not demonstrate any obvious potential as an asthma biomarker in adolescents and young adults with asthma. To understand the possible proasthmatic functions of MFAP4, further investigation in specific asthma phenotypes and the underlying molecular mechanisms is warranted.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688087 | PMC |
http://dx.doi.org/10.1002/iid3.254 | DOI Listing |
Eur Clin Respir J
January 2025
Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark & Odense University Hospital, Odense, Denmark.
Objectives: To evaluate the Medical Research Council (MRC) dyspnoea scale and serum Microfibrillar-associated protein 4 (MFAP4) levels for the detection of respiratory impairment in newly diagnosed rheumatoid arthritis (RA).
Methods: Patients underwent blood tests, pulmonary function tests (PFT) and dyspnoea assessment using the MRC scale. Respiratory impairment was defined as a diffusion capacity of the lungs for carbon monoxide (DLCO) <80% predicted or FEV1/FVC <70%.
Rheumatol Int
December 2024
Department of Rheumatology, Odense University Hospital, Odense, Denmark.
Background: Currently, there are no reliable biomarkers for predicting treatment response in chronic inflammatory diseases (CIDs).
Objective: To determine whether serum microfibrillar-associated protein 4 (MFAP4) levels can predict the treatment response to biological therapy in patients with CIDs.
Methods: The BELIEVE study was originally designed as a prospective, multi-center cohort study of 233 patients with either rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, Crohn's disease, or ulcerative colitis, initiating treatment with a biologic agent (or switching to another).
Mult Scler
December 2023
Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Background: Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the human central nervous system (CNS).
Objectives: We determined MFAP4 CNS expression and measured cerebrospinal fluid (CSF) and serum levels.
Methods: Tissue was sampled at autopsy from patients with acute multiple sclerosis (MS) ( = 3), progressive MS ( = 3), neuromyelitis optica spectrum disorder (NMOSD) ( = 2), and controls ( = 9), including 6 healthy controls (HC).
JGH Open
March 2023
Laboratory of Cellular and Molecular Physiopathologies (CAMP), Department of Life and Earth Sciences, Faculty of Sciences Lebanese University Beirut Lebanon.
Background And Aim: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD-associated outcome. Microfibrillar-associated protein 4 (MFAP4) is a glycoprotein located in the extracellular matrix.
View Article and Find Full Text PDFJ Cancer Res Ther
December 2022
Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine; NHC Key Laboratory of Combined Multi-Organ Transplantation; Institute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Objective: Revealing microfibrillar-associated protein 4 (MFAP4)'s function and its clinical significance in hepatocellular carcinoma (HCC).
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to evaluate MFAP4 mRNA and protein expression in paired HCC and paracarcinoma tissues, respectively. MFAP4 serum concentration was detected using enzyme-linked immunosorbent assays in healthy people (n = 30), cirrhosis (n = 15) and HCC patients (n = 80).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!